摘要
视神经脊髓炎(NMO)及其谱系疾病(NMOSD)是一种主要累及视神经和脊髓的炎性脱髓鞘疾病,以往多认为是多发性硬化的一个变异型,随着NMO-IgG及其特异性的靶点水通道蛋白4(AQP-4)的发现,NMO作为一种新的中枢神经系统自身免疫疾病而独立于多发性硬化,最近研究显示B细胞对NMO-IgG的产生起主导作用。利妥昔单抗作为NMOSD的缓解期治疗药物,主要通过耗竭B细胞来减少NMOSD的复发次数,但仍需进一步明确该药物在NMOSD中的作用机制、用药剂量、安全性,以便更有效地指导临床治疗。
Neuromyelitis optica （NMO）spectrum disorders （NMOSD）is a major involving the optic nerve and spinal cord inflammatory demyelinating disease. Many people thought it was a variant of multiple sclerosis,with the discovery of NMO-IgG and aquaporin-4 （AQP-4）, NMO as a new autoimmune disease of the central nervous system and is independent of the multiple sclerosis, recent studies have shown that B cell plays a leading role in producing NMO-IgG. Rituximab as NMOSD remission therapy, primarily relapsed NMOSD by depletions of the B-cell number,but the mechanism of action,dosage and security of the drug in the NMOSD still need to be further clarified to guide the clinical treatment more effectively.
出处
《中华脑科疾病与康复杂志（电子版）》
2015年第6期39-42,共4页
Chinese Journal of Brain Diseases and Rehabilitation（Electronic Edition）
关键词
视神经脊髓炎
药理作用分子作用机制
治疗结果
利妥昔单抗
Neuromyelitis optica
Molecular mechanisms of pharmacological action
Treatment outcome
Rituximab
